# David R. Jones

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/david-r-jones-2/

## Facts

| Field | Value |
| --- | --- |
| Citations | 67,409 |
| Field | Lung Cancer Diagnosis and Treatment |
| h-index | 103 |
| i10-index | 505 |
| Last Known Institution | Memorial Sloan Kettering Cancer Center |
| OpenAlex ID | https://openalex.org/A5064240414 |
| ORCID iD | https://orcid.org/0000-0002-3318-0146 |
| Works | 1,250 |

## Researcher papers

Showing 12 of 13.

- [Signatures of mutational processes in human cancer](https://scholariq.org/papers/signatures-of-mutational-processes-in-human-cancer/)
- [Neoadjuvant PD-1 Blockade in Resectable Lung Cancer](https://scholariq.org/papers/neoadjuvant-pd-1-blockade-in-resectable-lung-cancer/)
- [High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants](https://scholariq.org/papers/high-intensity-sequencing-reveals-the-sources-of-plasma-circulating-cell-free/)
- [Morbidity and Mortality of Major Pulmonary Resections in Patients With Early-Stage Lung Cancer: Initial Results of the Randomized, Prospective ACOSOG Z0030 Trial](https://scholariq.org/papers/morbidity-and-mortality-of-major-pulmonary-resections-in-patients-with-early/)
- [Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients](https://scholariq.org/papers/genomic-characterization-of-metastatic-patterns-from-prospective-clinical/)
- [Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)](https://scholariq.org/papers/pathologic-features-of-response-to-neoadjuvant-anti-pd-1-in-resected-non-small/)
- [A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab](https://scholariq.org/papers/a-phase-i-trial-of-regional-mesothelin-targeted-car-t-cell-therapy-in-patients/)
- [Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers](https://scholariq.org/papers/transcriptional-programs-of-neoantigen-specific-til-in-anti-pd-1-treated-lung/)
- [Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non–small cell lung cancer](https://scholariq.org/papers/initial-results-of-pulmonary-resection-after-neoadjuvant-nivolumab-in-patients/)
- [Primary Payer Status Affects Mortality for Major Surgical Operations](https://scholariq.org/papers/primary-payer-status-affects-mortality-for-major-surgical-operations/)
- [Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer](https://scholariq.org/papers/overall-survival-with-circulating-tumor-dna-guided-therapy-in-advanced-non-small/)
- [Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer](https://scholariq.org/papers/neoadjuvant-nivolumab-plus-ipilimumab-in-resectable-non-small-cell-lung-cancer/)

## Researcher topics

- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

## Researcher university

- [Memorial Sloan Kettering Cancer Center](https://scholariq.org/institutions/memorial-sloan-kettering-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.